Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<keyword id="19900617" type="General" weightage="20" keywordseo="stock-markets" source="keywords">Stock markets</keyword> showed resilience on Monday, closing in green after a flat and negative start to the trading day. The benchmark indices, <keyword id="19896382" type="General" weightage="100" keywordseo="Sensex" source="keywords">Sensex</keyword> and <keyword id="19896381" type="General" weightage="20" keywordseo="Nifty" source="keywords">Nifty</keyword>, rebounded from intraday lows, driven by significant gains in the auto and pharmaceutical sectors. The BSE Sensex ended the day with an uptick of 131.18 points closing at 77,341.08. Meanwhile, the broader NSE Nifty 50 climbed 36.75 points to finish at 23,537.85. Both indices initially opened on a cautious note but gathered momentum as the day progressed, reflecting renewed <keyword id="20322632" type="General" weightage="20" keywordseo="investor-confidence" source="keywords">investor confidence</keyword>. Throughout the trading session, volatility was a defining feature, with sectors like Auto, <keyword id="19933821" type="General" weightage="20" keywordseo="pharma" source="keywords">Pharma</keyword>, and FMCG showing notable strength. The Nifty <keyword id="19979339" type="General" weightage="20" keywordseo="auto-sector" source="keywords">Auto sector</keyword> registered gains of 0.44 per cent, while the Pharma sector increased by 0.39 per cent, and FMCG surged by 0.53 per cent. These sectors' performance was instrumental in counterbalancing the losses experienced in the Media sector, which faced a steep decline of over 1 per cent. In the broader markets, the Nifty SmallCap index edged up by a modest 0.06 per cent, and the Nifty MidCap index saw a more robust increase of 0.18 per cent. These movements underscore a cautiously optimistic sentiment among investors, who are showing a selective preference for mid and small-cap stocks amidst broader market uncertainties. The Nifty 50 index saw 30 stocks advancing while 20 declined, indicating a mixed yet overall positive <keyword id="20127603" type="General" weightage="20" keywordseo="market-sentiment" source="keywords">market sentiment</keyword>. Among the top performers were <keyword id="19993913" type="General" weightage="20" keywordseo="Mahindra-Mahindra" source="keywords" meta.keywordsubtype="org" meta.entityname="Mahindra &amp; Mahindra" meta.hostid="261" meta.entityid="Mahindra &amp; Mahindra">Mahindra &amp; Mahindra</keyword> (M&amp;M), Shriram Finance, Grasim Industries, Power Grid Corporation, and Sun Pharma. M&amp;M benefited from a buoyant auto sector, while Shriram Finance posted strong gains, contributing to the positive momentum in financial services. Grasim Industries gained due to optimism in the industrial and chemical sectors, and Power Grid Corporation saw a boost from expectations of increased infrastructure spending. Sun Pharma, a key player in the <keyword id="20598346" type="General" weightage="20" keywordseo="pharmaceutical-sector" source="keywords">pharmaceutical sector</keyword>, ended the day on a high note, reflecting the sector's overall strength. On the downside, notable laggards included IndusInd Bank, Cipla, AdPorts and SEZ, Coal India, and Tata Steel. IndusInd Bank suffered from profit-taking and sector-specific challenges, while Cipla faced selling pressure despite the sector's gains. Adani Ports and SEZ experienced a downturn due to broader market concerns over port operations, Coal India declined amid global pressures on fossil fuels, and Tata Steel faced challenges in the metals and mining sector. Technical analysis suggests that the Nifty has been consolidating within a range of 23,300 to 23,600, indicating a phase of indecisiveness among investors. Market analysts predict that a breakout above 23,600 could propel the index towards the 24,000 mark in the short term, signaling a bullish sentiment. Conversely, a drop below 23,300 might lead to a downside correction towards 22,750. Globally, markets presented mixed cues with European shares posting gains, driven by strength in the automobile and banking sectors. In contrast, Bitcoin experienced a sudden 4 per cent decline, trading at $61,094, highlighting ongoing volatility in the cryptocurrency market. Varun Aggarwal, founder and managing director, Profit Idea, said, "Oil prices edged higher, fueled by expectations of increased demand during the summer months and ongoing geopolitical tensions. Investor sentiment was bolstered by positive economic indicators, including stable industrial output and optimistic forecasts for the upcoming monsoon season. However, concerns over a potential global economic slowdown and rising inflation continue to loom, keeping investors cautious." Despite a rocky start, Indian stock markets managed to close on a positive note, driven by sector-specific gains and encouraging global cues. Investors will be closely monitoring further market signals and <keyword id="22037163" type="General" weightage="20" keywordseo="economic-developments" source="keywords">economic developments</keyword> in the coming days.

Stock markets end on positive note despite early setbacks

<keyword id="15160768" type="General" weightage="20" keywordseo="presvu" source="Orion">PresVu</keyword> eye drops, developed by <keyword id="20007796" type="General" weightage="20" keywordseo="entod-pharmaceuticals" source="keywords">Entod Pharmaceuticals</keyword>, were launched with considerable media attention earlier this month as a novel solution for <keyword id="23035383" type="General" weightage="20" keywordseo="presbyopia" source="keywords">presbyopia</keyword>. Presbyopia is a condition where individuals aged 40 and above experience difficulty focusing on nearby objects, often requiring reading glasses. PresVu claimed to reduce or eliminate the need for these glasses, offering an alternative through its active ingredient, 1.25% Pilocarpine, which temporarily contracts the pupil, improving near vision. Entod Pharmaceuticals earlier announced that the product had approval from the <keyword id="20047866" type="General" weightage="20" keywordseo="drug-controller-general-of-india" source="keywords">Drug Controller General of India</keyword> (<keyword id="20046022" type="General" weightage="20" keywordseo="dcgi" source="keywords">DCGI</keyword>). These announcements created substantial buzz, as the treatment promised a non-invasive solution to a common problem affecting millions of people. <h2>Regulatory backlash</h2>The situation escalated when the Drug Controller General of India suspended the marketing and distribution licence of PresVu eye drops. The suspension was issued due to unauthorised promotional campaigns by Entod, which made unverified claims about the drug's capabilities. The company had reportedly promoted PresVu not as a prescription drug, but as an over-the-counter (OTC) solution that could potentially replace reading glasses — a claim that regulators found highly misleading. The DCGI expressed concerns that such promotions could lead to misuse, with patients potentially self-administering the product without medical guidance, raising significant safety concerns. Furthermore, the regulatory body pointed out that while the product had been approved as a prescription drug, the marketing blitz implied it was a quick-fix solution available to anyone, which it was not. <h2>Entod Pharmaceuticals responds</h2>Entod Pharmaceuticals quickly defended itself against these allegations, maintaining that their marketing campaign was based on the information cleared by the DCGI. According to Entod, the promotion highlighted only the approved uses of the <keyword id="4537914" type="General" weightage="20" keywordseo="eye-drop" source="Orion">eye drop</keyword>, and any misconceptions arose from how the media and public interpreted the information. The company asserted that it would challenge the suspension in court, emphasising that other pharmaceutical companies frequently follow similar marketing practices without facing such scrutiny. In a statement, Entod’s CEO, <keyword id="21011592" type="General" weightage="20" keywordseo="nikkhil-k-masurkar" source="keywords">Nikkhil K Masurkar</keyword>, clarified that the company had conducted phase 3 clinical trials in India to ensure the product’s safety and efficacy. <div type="Article" hostid="261" msid="113251803" title="The next big market for weight-loss drugs: children" mstype="2" mssubtype="0"></div>“Our approval by DCGI was based on a valid controlled clinical trial in 234 patients which was successful in showing efficacy and safety of these eye drops in patients of Presbyopia, who used these drops without eyeglasses and could read additional lines on Snellen's chart which is yardstick of near vision impairment,” Masurkar commented in a statement. He insisted that the product’s promotional activities had followed standard protocols and blamed the viral nature of media reports for blowing the issue out of proportion. Despite these defences, the product remained suspended pending further investigations. "Such eye drops with the same active ingredient and same concentration have been approved by the US <keyword id="19918726" type="General" weightage="20" keywordseo="fda" source="keywords">FDA</keyword> and marketed in the US for the last three years without any serious complications. FDA didn’t take any action on the companies marketing the same in the USA,” Masurkar further elaborated. <h2>Public and expert reactions</h2>The controversy garnered widespread attention, particularly from medical professionals. The Liver Doc, a prominent liver specialist that takes to social media to debunk pseudoscientific claims, criticised the situation on X (former Twitter), warning about the dangers of exaggerated medical claims in advertising. The doctor’s tweet emphasised that blaming Indian media for blowing Entod’s claims out of proportion was “shameless”, noting that the media merely reported exactly what the company had themselves claimed earlier. <div type="twitter" handle="theliverdr" handlename="theliverdr" favoritecount="0" retweetcount="0" id="1833828866210849170"></div>As of September 12, 2024, the suspension of PresVu's marketing approval remains in place. Entod Pharmaceuticals is preparing to contest the decision in court, hoping to reinstate its flagship product in the Indian market. The regulatory investigation continues, with the DCGI seeking clarification on the exact nature of the promotions and whether they indeed violated ethical standards. <div type="Article" hostid="261" msid="113229771" title="China&amp;#39;s drug regulator clears mpox vaccine; to undergo clinical trial" mstype="2" mssubtype="0"></div>Despite Entod’s defence, the controversy has raised important questions about the marketing of prescription drugs in India, with regulators, the media, and the public closely watching how this case will evolve. The outcome could set a precedent for how pharmaceutical companies in India can market innovative treatments, particularly when dealing with sensitive areas like vision correction.

PresVu eye drops: Why has a pharma company fallen in controversy for claiming to cure near-sightedness?

India is on the brink of a significant medical innovation with the upcoming launch of <keyword id="23029757" type="General" weightage="20" keywordseo="PresVu-eye-drops" source="keywords">PresVu eye drops</keyword>, a groundbreaking treatment aimed at reducing dependency on <keyword id="23034012" type="General" weightage="20" keywordseo="reading-glasses" source="keywords">reading glasses</keyword>. Developed by Mumbai-based <keyword id="20007796" type="General" weightage="20" keywordseo="Entod-Pharmaceuticals" source="keywords" meta.keywordsubtype="org" meta.entityname="Entod Pharmaceuticals" meta.hostid="261" meta.entityid="Entod Pharmaceuticals">Entod Pharmaceuticals</keyword>, PresVu has recently received approval from the Drug Controller General of India (DCGI) and is scheduled to hit the market in early October 2024. <h3 style="line-height:1.2;margin-top:14pt;margin-bottom:4pt;">What is PresVu?</h3>PresVu eye drops are designed to treat <keyword id="23035383" type="General" weightage="20" keywordseo="presbyopia" source="keywords">presbyopia</keyword>, a common age-related condition that affects the eye's ability to focus on nearby objects. This condition, which typically begins in the early 40s, leads to a gradual decline in <keyword id="23035385" type="General" weightage="20" keywordseo="near-vision" source="keywords">near vision</keyword>, making reading glasses a necessity for millions. As per estimates, nearly one third of Indian adults suffer from the condition. PresVu offers a novel solution, aiming to restore visual independence to those suffering from mild to moderate presbyopia. <div type="Article" hostid="261" msid="112800837" title="Scientists want to help drug addicts recover — by giving them psychedelics" mstype="2" mssubtype="0"></div><h2>How does it work?</h2>The drug contains <keyword id="23035386" type="General" weightage="20" keywordseo="pilocarpine-hydrochloride" source="keywords">pilocarpine hydrochloride</keyword> — a plant-derived compound that has been used for decades to treat various eye conditions and dry mouth. The drops are intended for daily use, with effects lasting several hours, allowing users to perform tasks like reading without the need for glasses. As per the company, the effects of the drops will be apparent within 15 minutes, but complete benefits are only apparent after 15 days of use. The treatment has been thoroughly tested in clinical trials across India and has shown promising results in improving near vision. <div type="Article" hostid="261" msid="112738885" title="India bans 156 commonly used combination drugs citing possible risks to humans" mstype="2" mssubtype="0"></div><h2>Market impact and accessibility</h2>The introduction of PresVu is expected to make a significant impact in India, where the prevalence of presbyopia is rising. As per media sources, each vial will be priced at Rs 345, making it an affordable alternative to reading glasses. Each vial is designed to last about a month, making it a cost-effective solution for long-term use. Entod Pharmaceuticals has ambitious plans for PresVu, targeting not just the Indian market but also emerging markets in Africa and Southeast Asia. The company sees this as a step towards becoming a global innovator in ophthalmology, with future plans to out-licence products in the US market. (Editor's note: PresVu eye-drops have since been suspended by the DCGI for making exaggerated marketing claims related to the product)

Say bye-bye to reading glasses! Mumbai drug-maker to soon introduce eye drops to treat presbyopia in India

In a recent notification, the <keyword id="20004725" type="General" weightage="100" keywordseo="NSE" source="keywords">NSE</keyword> (National Stock Exchange) noted that markets will remain closed on Wednesday, November 20, 2024, on account of state elections taking place in Maharashtra. However, <keyword id="19895774" type="General" weightage="20" keywordseo="BSE" source="keywords">BSE</keyword> has issued no notification on this matter so far. However, given how both the exchanges largely operate in sync, BSE is likely to declare a holiday as well. Before the elections, both BSE and NSE will be shut for trading on November 15 as well, on account of <keyword id="23718443" type="General" weightage="20" keywordseo="Guru-Nanak-Jayanti" source="keywords">Guru Nanak Jayanti</keyword>. Next month, the bourses will remain closed for regular trade on Christmas, i.e., December 25. Earlier this week, Brihanmumbai Municipal Corporation (BMC) mandated that all businesses and workplaces in Mumbai should grant paid leave on November 20, 2024, to all its employees so that they can participate in state elections. Failure to do so could mean penalties for employers. All the 288 states in the Maharashtra state assembly are set to go to polls in a single phase on November 20. <h2>Markets close the week on muted note </h2>Both Nifty and Sensex closed the week on a damp note, with Nifty dipping 0.21% to close at 24,148.20 points. On the other hand, Sensex also slipped below the 80,000 mark to close the week at 79,486.32 points. Of the 50 stocks that constitute Nifty, 23 stocks advanced during the day, while 27 saw declines. However, this week has not been all that bad for the markets, with Nifty rising 0.31% and Sensex inching up 0.65% during the last 5 days. All broad market indices fell during today's trade, with smallcaps falling by over 1.5%, while midcaps also closed the day over 1% down. As for sectoral indices, most of them ended the week in reds, with realty and media losing over 2% during trading today. Pharmaceuticals, healthcare, and consumer durables recorded marginal upticks during the day, inching up by 0.07%, 0.22%, and 0.41%, respectively. FIIs (<keyword id="19932515" type="General" weightage="20" keywordseo="foreign-institutional-investors" source="keywords">foreign institutional investors</keyword>) continued their selling spree today as well. In this month so far, FIIs have been net cash sellers, offloading around Rs 16,445.49 crore. DIIs (domestic institutional investors) have stepped in to maintain some balance by becoming net buyers worth Rs 12,265.74 crore in November till date. Shrikant Chouhan, Head Equity Research, Kotak Securities, explains that global market sentiment saw sharp volatility in the aftermath of Republicans winning all three branches of the US government, resulting in rising US bond yields and the dollar, as well as the US equity markets beating most EMs. Meanwhile, the Q2 FY25 earnings season continued to remain weak, with more misses than hits observed. <keyword id="20993056" type="General" weightage="20" keywordseo="FPI-flows" source="keywords">FPI flows</keyword> are expected to remain volatile for some time to come. Amidst emerging markets, only Brazil saw inflows worth $115 million between November 1 and 7, 2024.

Markets to remain shut on November 20 due to Maharashtra elections

<keyword id="22119701" type="General" weightage="20" keywordseo="Emcure-Pharma" source="keywords">Emcure Pharma</keyword>, where <keyword id="20292047" type="General" weightage="20" keywordseo="namita-thapar" source="keywords">Namita Thapar</keyword>, of Shark Tank India fame, serves as a member of the promotor group, opens for subscription today. The company aims to raise Rs 800 crore via fresh issue of 0.79 crore shares and Rs 1,152.03 crore via offer for sale, wherein promotors will offload around 1.14 crore shares in the market. Emcure Pharma's <keyword id="19898327" type="General" weightage="20" keywordseo="IPO" source="keywords">IPO</keyword> will close for subscription on on 5th July, with allotment to be finalised by 8th June, and listing on BSE and NSE scheduled for 10th July. But should you subscribe to this IPO? What are the experts saying? Lets find out <h2>About Emcure Pharma</h2>With 13 manufacturing and 5 research facilities across the country, Emcure Pharma develops, manufactures and markets a wide range of <keyword id="20006091" type="General" weightage="20" keywordseo="pharmaceuticals" source="keywords">pharmaceuticals</keyword>, which includes orals, injectables and biotherapeutics. The company, which recorded the highest domestic sales in <keyword id="648555" type="General" weightage="20" keywordseo="gynecology" source="Orion">gynecology</keyword> and <keyword id="185429" type="General" weightage="20" keywordseo="human-immunodeficiency-virus" source="Orion">human immunodeficiency virus</keyword> (HIV) antivirals therapeutic areas in India in FY24, has its target market in about 70 countries. The company's total revenue from operation, as of 31st March 2024, stood at 6,658.251 crore, up sharply from Rs 5,985.811 crore it earned as of 31st March, 2023. As of 31st March, 2024, 48.28% of its revenue stemmed from sales in India, while 51.72% of its revenue came from sales outside India. The company also holds around 220 patents, alongside having 30 pending patent applications in several countries. Emcure Pharma had generated a profit of Rs 527.57 crore in FY24, slightly down from Rs 561.84 crore in FY23. The company intends to utilise the proceedings from IPO for general corporate purposes, and repaying and prepaying some loans. The company reported Profit After Tax margins of 11.81% in FY22, 9.31% in FY23 and 7.86% in FY24. <h2>How much can you invest?</h2>Retail investors can buy a minimum of 1 lot (14 shares) at Rs 14,112, or 14 lots (196 shares) at Rs 1,97,586. 50% of the issue has been allotted for QIBs (qualified institutional buyers), while 15% has been reserved for non-institutional investors, and 35% has been set aside for retail investors. The share's price band has been kept between Rs 960 and Rs 1008. <h2>What are the risks? </h2>Despite the company's strong bottom line performance, it is not without its fair share of risks. For starters, the company operates in the heavily regulated and scrutinised space of pharmaceutical development and manufacturing. Any failure to renew their licenses or permits, either in India or abroad, could have adverse business implications. Some other risks include: <ul><li>The company's heavy reliance on third parties for distribution and marketing of its products. A slight change in that could impact the company's supply and product pricing. </li><li> Emcure has experienced negative cash flows in the past and may continue to do so in the future.</li><li>Any manufacturing, quality control issues, or the inability to timely commercialize their research could dent their reputation and business, while opening them to strict regulatory action. </li><li>The company has significant working capital needs, which is exacerbated by its negative cash flows. </li><li>Emcure has issued show cause notices by the Regional Director, MCA on account of non-compliance with Companies Act. Additionally, they have some civil proceedings pending in the US as well.</li><li>Certain therapeutic areas contribute to a more significant portion of the company’s total revenue in India, and their business may be adversely affected if their products in these therapeutic areas do not perform as expected.</li></ul><h2>What are the experts saying? </h2>As per the IPO note of Master Capital Service Ltd, the IPO is fairly valued relative to its listed peers, and that the IPO should be subscribed to from a long-term perspective. "The company is looking to utilize the fresh proceeds to pare down their long-term debt and bring it to zero. The company has gone from strength to strength historically with a focus on major therapeutic areas such as gynaecology and is looking to double down on its strengths to fuel its future growth and expand its margins", it continued. Swastika Investmart Ltd also recommends subscribing to this IPO from a long-term horizon. "<keyword id="20737581" type="General" weightage="20" keywordseo="Emcure-Pharmaceuticals" source="keywords" meta.keywordsubtype="org" meta.entityname="Emcure Pharmaceuticals" meta.hostid="261" meta.entityid="Emcure Pharmaceuticals">Emcure Pharmaceuticals</keyword> is a prominent player in the domestic and international pharmaceutical markets. The company boasts a large, diversified, and fast-growing product portfolio, coupled with proven brand-building capabilities and strong R&amp;D infrastructure. Emcure has demonstrated consistent top-line growth, although recent profitability has seen a slight decline due to interest expenses and depreciation". "However, some key risks require careful consideration. The pharmaceutical industry is highly regulated, and Emcure faces potential disruptions to its raw material supply chain. Additionally, the company relies on third parties for product marketing and distribution. Considering the company's strengths, growth trajectory, and the potential for debt reduction post-IPO, we view the P/E valuation of 36.6x as reasonable. We recommend applying for this IPO with a long-term view", it continued. As stock analyst Dilip Dawda highlights, Emcure is a R &amp; D driven pharma company that has posted continuous growth. "However, its bottom line posted declining trends with higher provisions for interest and depreciations. Based on FY24 earnings, the issue appears fully priced. Investors may park funds for the medium to long term rewards", he advises.

Emcure Pharma opens for subscription today: Should you subscribe? Know all about it here

<keyword id="22202960" type="General" weightage="20" keywordseo="Bain-Capital-backed" source="keywords">Bain Capital-backed</keyword> <keyword id="20737581" type="General" weightage="20" keywordseo="Emcure-Pharmaceuticals" source="keywords" meta.keywordsubtype="org" meta.entityname="Emcure Pharmaceuticals" meta.hostid="153" meta.entityid="Emcure Pharmaceuticals">Emcure Pharmaceuticals</keyword> on Friday said it has fixed a price band of Rs 960 to Rs 1,008 per share for its Rs 1,952-crore <keyword id="19913114" type="General" weightage="20" keywordseo="Initial-Public-Offering" source="keywords">Initial Public Offering</keyword> (<keyword id="19898327" type="General" weightage="20" keywordseo="IPO" source="keywords">IPO</keyword>). The initial share sale will be available for public subscription during July 3-5 and the bidding for anchor investors will open for a day on July 2, the company announced. The IPO comprises fresh issuance of equity shares worth Rs 800 crore and an Offer For Sale (OFS) of 1.14 crore equity shares to the tune of Rs 1,152 crore, at the upper end of the price band, by promoters and existing shareholders. This aggregates the total public size to Rs 1,952 crore. Those selling shares in the OFS include promoter Satish Mehta and investor BC Investments IV Ltd, an affiliate of US-based private equity major Bain Capital. Currently, Satish Mehta holds a 41.85 per cent stake in the company and BC Investments owns a 13.07 per cent stake. Proceeds of the fresh issue will be used towards payment of debt and for general corporate purposes. Brokerage houses have pegged the company's market capitalisation to over Rs 19,000 crore post-issue. The Pune-based firm Emcure Pharmaceuticals is engaged in developing, manufacturing, and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. Employee portion has been reserved up to 108,900 equity shares in the IPO. Besides, half of the issue size has been reserved for qualified institutional investors (QIBs), 35 per cent for retail investors and the remaining 15 per cent for non-institutional investors. Further, investors can bid for a minimum of 14 shares and in multiples of 14 shares thereafter. Kotak Mahindra Capital Company, Jefferies India, Axis Capital, and JP Morgan India are the book-running lead managers to the issue. The equity shares of the company are expected to list on the BSE and NSE on July 10. Earlier this month, the company received Sebi's go-ahead to float initial share sale.

Bain Capital-backed Emcure Pharma to float ₹1,952-crore IPO on July 3

<keyword id="20270096" type="General" weightage="20" keywordseo="equity-benchmark-indices" source="keywords">Equity benchmark indices</keyword> <keyword id="19896382" type="General" weightage="20" keywordseo="Sensex" source="keywords">Sensex</keyword> and <keyword id="19896381" type="General" weightage="100" keywordseo="Nifty" source="keywords">Nifty</keyword> began the trade on a positive note on Friday but later pared gains to quote lower amid a muted trend in <keyword id="19908188" type="General" weightage="20" keywordseo="global-markets" source="keywords">global markets</keyword> and selling in <keyword id="19963566" type="General" weightage="20" keywordseo="IT-stocks" source="keywords">IT stocks</keyword>. Market analysts said <keyword id="19900618" type="General" weightage="20" keywordseo="investors" source="keywords">investors</keyword> are awaiting cues from the US Federal Reserve Chair Jerome Powell's comments at Jackson Hole Symposium. The 30-share <keyword id="19950208" type="General" weightage="20" keywordseo="BSE-Sensex" source="keywords">BSE Sensex</keyword> opened 37.32 points or 0.05 per cent higher at 81,090.51 points. The NSE Nifty gained 18.25 points to 24,829.75. Later, both the benchmark indices pared their early gains and were trading in the negative territory. The BSE benchmark quoted 117.82 points or 0.15 per cent lower at 80,935.37 and the Nifty traded at 24,776.95, down by 34.55 points. From the Sensex pack, <keyword id="19906778" type="General" weightage="20" keywordseo="Infosys" source="keywords" meta.keywordsubtype="org" meta.entityname="Infosys" meta.hostid="261" meta.entityid="Infosys">Infosys</keyword>, Titan, Tata Steel, UltraTech Cement, ITC, Tata Consultancy Services, Tech Mahindra and Asian Paints were the laggards. On the contrary, Tata Motors, Reliance Industries, Sun Pharmaceuticals, Mahindra &amp; Mahindra, Bajaj Finserv and ICICI Bank were among the gainers. "Globally the market's focus on Friday will be on US Federal Reserve Chair Jerome Powell's comments at Jackson Hole on the economy and the possible rate cut trend. Powell is likely to sound dovish indicating a rate cut in September," V K Vijayakumar, Chief Investment Strategist, Geojit Financial Services, said. In Asian markets, Tokyo, Shanghai were trading higher, while Hong Kong and Seoul were quoting in the red territory on Friday. The US markets were closed lower on Thursday. Foreign Institutional Investors (FIIs) bought equities worth Rs 1,371.79 crore on Thursday, according to exchange data. Meanwhile, Domestic Institutional Investors (DIIs) again bought equities worth Rs 2,971.80 crore on Thursday. Global oil benchmark Brent crude rose 0.06 per cent to USD 77.27 a barrel. On Thursday, the 30-share BSE index rose 147.89 points to close at 81,053.19, registering gains for the third day in a row. Extending gains to a sixth session in a row, the NSE Nifty went up by 41.30 points to end at a two-week high of 24,811.50.

Markets pare early gains; trade lower amid muted global market trend

One must have to be living under a rock if they haven’t yet come across those reels of “health” influencers raving about the many health benefits of <keyword id="21778414" type="General" weightage="20" keywordseo="omega-3" source="keywords">omega-3</keyword> and <keyword id="21766014" type="General" weightage="20" keywordseo="fish-oil-supplements" source="keywords">fish oil supplements</keyword>. From aiding weight loss in those suffering from PCOS to promoting bone and skin health, there’s little these tiny golden capsules can’t achieve, as far as they are concerned. To their credit, fish oil supplements do seem to be helpful to a certain extent and their role in protecting against <keyword id="21778415" type="General" weightage="20" keywordseo="cardiovascular-risks" source="keywords">cardiovascular risks</keyword> is well documented. However, a recent <a href="https://bmjmedicine.bmj.com/content/3/1/e000451">study</a> conducted by a team of international researchers has thrown the fish oil supplement's presumed safety into question. And understandably, ripples are being caused. <cmsannotation type="cmsannotation" annotationid="Contradictory results surprise scientists" comment="subhead" text="Contradictory results surprise scientists">Contradictory results surprise scientists </cmsannotation>After monitoring 400,000 participants in the UK Biobank for an average of 12 years, researchers were in for a surprise! The findings revealed a 13% higher risk of <keyword id="20710883" type="General" weightage="20" keywordseo="atrial-fibrillation" source="keywords">atrial fibrillation</keyword> — irregular heart rhythm — and a 5% heightened risk of strokes in those with no prior history of cardiovascular disease. But for individuals who already had <keyword id="19898369" type="General" weightage="20" keywordseo="heart-disease" source="keywords">heart disease</keyword>, the fish oil supplements resulted in a 15% lower risk of progression from atrial fibrillation to heart attack, and 9% lesser chances of advancing from heart failure to death. This is in line with previous studies indicating how Omega-3 fatty acids, especially EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), are beneficial for reducing cardiovascular complications. However, there is a catch: the study found mixed results for the effects of omega-3 supplements. Interestingly, women and non-smokers who were healthy at the outset saw 6% higher risks of going on to have heart attacks, heart failure or strokes. Conversely, older people and men seemed to have derived greeted benefits from fish oil, with the transition from good health to death being 11% and 7% lower respectively. It is important to note that this study is based entirely on data from mostly white people, so it doesn’t precisely account for the impacts of fish oil supplements on other ethnicities. Then again, scepticism about the side effects of fish oil supplements on people with no history of heart disease isn’t new. Groups that have traditionally consumed a lot of fish containing omega-3 fatty acids have been known to have lower instances of heart disease. Fish oil supplements, the pill form of these polyunsaturated fats, have a decades-long track record of proven benefits for heart health — for people who already have these risks being key here. Now, according to a 2023 Lancet study, cardiovascular diseases are the leading cause of death and disability in India. In that regard, omega-3 supplements do have quite a bit of merit in the Indian market. Nutraceutical businesses have already gained traction cross-country and are growing increasingly popular. What’s more, this market is only expected to grow further due to the rise in product knowledge, disposable income and the desire for <keyword id="20523304" type="General" weightage="20" keywordseo="preventive-medicine" source="keywords">preventive medicine</keyword> and self-treatment. <cmsannotation type="cmsannotation" annotationid="Are over-the-counter products safe?" comment="subhead" text="Are over-the-counter products safe?">Are over-the-counter products safe? </cmsannotation>Based on older studies, as well as the recent one, the risks that fish oil supplements pose do outweigh the benefits in healthy people. So if you’ve been chugging fish oil capsules in hopes that it would help you circumvent health complications in the future, it might be a good idea to take a step back and think. The problem with <keyword id="21778416" type="General" weightage="20" keywordseo="over-the-counter-supplements" source="keywords">over-the-counter supplements</keyword> is that there’s no real proof that they are actually helping with anything. And given recent controversies in some of the food products being manufactured in India, caution regarding food-grade products is paramount. There is no need to villainise fish oil supplements just yet. However, getting advice and a prescription from a certified healthcare professional who knows your specific health conditions might be a better idea than just relying on half-baked and generalised information from the internet. Furthermore, opting for <keyword id="21778417" type="General" weightage="20" keywordseo="pharmaceutical-grade-fish-oils" source="keywords">pharmaceutical-grade fish oils</keyword> is considered a safer bet to take in high doses. Over-the-counter fish oil supplements contain a low dose (about 1 gram) of two different omega-3 fatty acids DHA and EPA. Prescription fish oil pills contain about 4 grams of either a DHA/EPA combo or pure EPA — the compounds mainly responsible for cleaning you of triglycerides. With a barrage of nutraceuticals having entered our pharmacies, we might need a lot more research in the Indian context to determine just how safe these fish oil supplements are. In the meantime, stay informed and stay safe.

Is it time we stopped taking over-the-counter fish oil supplements?

The country's drugs and <keyword id="20006091" type="General" weightage="20" keywordseo="pharmaceuticals" source="keywords">pharmaceuticals</keyword> exports increased 9.67 per cent year-on-year to USD 27.9 billion in 2023-24, even as the total exports dipped by 3 per cent in the last fiscal. According to the commerce ministry data, <keyword id="20988985" type="General" weightage="20" keywordseo="pharma-exports" source="keywords">pharma exports</keyword> in March grew by 12.73 per cent to USD 2.8 billion. In 2022-23, the exports stood at USD 25.4 billion. The top five export markets, for the sector during the last fiscal, are the US, the UK, the Netherlands, the United Kingdom, South Africa and Brazil. The US accounts for over 31 per cent of <keyword id="19895063" type="General" weightage="20" keywordseo="India" source="keywords">India</keyword>'s total pharma exports, followed by the UK and Netherlands (about 3 per cent each). In 2023-24, the outbound shipments also entered new geographies like Montenegro, South Sudan, Chad, Comoros, Brunei, Latvia, Ireland, Chad, Sweden, Haiti and Ethiopia. An industry expert said that increasing market opportunities and healthy demand in countries like the US are helping exports to record healthy growth rates month after month. Experts have said that India's pharmaceutical business may exceed USD 130 billion by 2030, supported by expanding market opportunities and heightened demand in the overseas markets. The business stood at over USD 50 billion for the 2022-23. On average, India exports pharma products worth USD 2-3 billion every month. India's pharmaceutical industry is the third largest by volume and the 13th largest by value in the world, producing more than 60,000 <keyword id="20581305" type="General" weightage="20" keywordseo="generic-drugs" source="keywords">generic drugs</keyword> across 60 therapeutic categories. The government has rolled out two production-linked incentive (<keyword id="19958919" type="General" weightage="20" keywordseo="pli" source="keywords">PLI</keyword>) schemes to promote domestic manufacturing of key pharmaceutical ingredients and generic medicines. SEE ALSO:<a href="https://www.businessinsider.in/tech/mobile/news/realme-narzo-70-narzo-70x-5g-smartphones-launched-in-india-starting-at-11999/articleshow/109557895.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/mobile/news/realme-narzo-70-narzo-70x-5g-smartphones-launched-in-india-starting-at-11999/articleshow/109557895.cms" target="_blank">Realme Narzo 70, Narzo 70X 5G smartphones launched in India starting at ₹11,999</a> <a href="https://www.businessinsider.in/tech/news/apple-let-loose-event-scheduled-for-may-7-ipads-expected-to-be-launched/articleshow/109553148.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/news/apple-let-loose-event-scheduled-for-may-7-ipads-expected-to-be-launched/articleshow/109553148.cms" target="_blank">Apple Let Loose event scheduled for May 7 – New iPad models expected to be launched</a><a href="https://www.businessinsider.in/tech/mobile/news/google-pixel-8a-may-be-more-expensive-than-its-predecessor-as-per-a-new-leak/articleshow/109499394.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/mobile/news/google-pixel-8a-may-be-more-expensive-than-its-predecessor-as-per-a-new-leak/articleshow/109499394.cms" target="_blank">Google Pixel 8a may be more expensive than its predecessor, as per a new leak</a>

India's pharma exports rise 10% to $27.9 bn in FY24

<ul class="summary-list"><li>Investors are worried that labor market weakness could thwart a soft landing.</li><li>However, Goldman Sachs' Joseph Briggs doesn't think there's reason for concern.</li></ul>As inflation creeps downward, investors are increasingly turning their attention to the labor market to look for clues of a soft landing.Both July and August employment data fell short of Wall Street expectations after revealing lower-than-expected job additions, sparking fears of a recession and sending stocks tumbling. The highly anticipated September jobs data will be released this Friday.Investors shouldn't be worried, though. Labor market fundamentals remain strong, according to Joseph Briggs, co-lead of Goldman Sachs' global economics team and a former Federal Reserve senior economist."If we take a broad assessment across a number of different labor market indicators, they are still roughly where they were from 2017 to 2019, and that was a pretty healthy labor market," Briggs said.In Briggs' view, the following three indicators point to a normalizing late-cycle labor market, and in turn, a strong economy.<h2 id="8324345f-3390-4c5f-b3f9-7002460cb3bb">3 signs of a healthy labor market</h2>Layoffs are one important indicator of the job market's health, and luckily, companies aren't laying off many workers right now.Both layoff rates and initial claims are hovering at or below pre-pandemic levels, Briggs pointed out. Initial claims, or first-time jobless claims filed by individuals seeking unemployment benefits, dropped to a four-month low of 218,000 last week.Low layoffs, in particular, are a positive sign because they help the economy avoid a dangerous feedback loop, Briggs said. Layoffs lead to decreased consumer spending, hurting companies, which leads to even more layoffs.Thankfully, the labor market isn't experiencing this sort of spiral right now. "We're not really seeing any signs on a widespread basis that employers are actually firing workers," Briggs said.On the contrary, consumer spending is quite robust, driven by continued job gains and wage growth, according to Briggs.Wage growth is improving and exceeding inflation this year, posting 3.5% year-over-year growth in August 2024. Real average weekly earnings increased 0.2% from July to August of this year. Briggs predicts that US workers could see 2.0 to 2.5% real income growth in the upcoming year.The US economy is also adding jobs at a steady pace that supports consumer spending, Briggs said. In August, 142,000 jobs were added, which Briggs sees as a healthy monthly increase. He expects the US economy to continue adding jobs at a rate of 140,000 to 150,000 a month. This pace of job growth isn't as aggressive as it was during the post-pandemic hiring frenzy, but that's to be expected as the labor market normalizes, and investors shouldn't take this development as an indicator of recession.Lastly, GDP growth remains strong, setting the stage for a favorable hiring environment. The US economy posted 3% annualized GDP growth in the second quarter of 2024, faster than the 1.4% growth rate in the first quarter and beating Wall Street expectations.Briggs is optimistic about future GDP growth as well. He expects the impacts of the Fed's rate-cutting cycle to start manifesting in the economy relatively quickly, boosting US GDP within the next few quarters.The overall economy has been improving in the past few months in anticipation of rate cuts and will continue to do so, in Briggs' opinion. Most notably, mortgage rates have been decreasing."The changes that we've seen over the last few months point to about a half-point boost to annualized GDP growth over the second half of 2024 and the first half of 2025," Briggs said."There are sectors of the economy that are still highly rate sensitive, and these will have a clear impact on GDP growth," he added.These areas include the housing market, consumer durables, small-cap companies, and industries such as software and pharmaceuticals. With multiple areas of the economy set to benefit from rate cuts, investors should be confident that a soft landing and strong labor market are in the cards.

These 3 indicators are pointing to a healthy labor market similar to the pre-pandemic boom, according to Goldman Sachs

<ul class="summary-list"><li>US stock indexes soared on Thursday as new jobless claims data raised investors' confidence.</li><li>The Dow rallied 683 points, while the S&amp;P 500 and Nasdaq rose 2.3% and 32.8%, respectively.</li></ul>US stocks rallied on Thursday, clawing back losses from the rout earlier in the week as <a target="_blank" href="https://markets.businessinsider.com/news/stocks/stock-market-today-jobless-claims-data-economy-labor-market-recession-2024-8">new jobs data boosted investors' confidence</a> in the labor market and the economy. The S&amp;P 500 jumped 2.3% for its best day since November 2022. The Nasdaq Composite spiked 2.8% and the Dow Jones Industrial Average. The 10-year Treasury yield ticked up two basis points to 3.98%, dipping slightly throughout the day after jumping above 4% earlier in the day. Fueling Thursday's gain was a drop in weekly jobless claims that soothed fears of an imminent recession after last week's surprise jump in the unemployment rate. Jobless claims last week dropped 17,000 to 233,00, marking the biggest fall in almost a year. The encouraging data comes after last week's disappointing nonfarm payroll report for July led to a historic selloff and sparked concerns of a recession.The information technology sector led the S&amp;P 500's rise, up 3.5%, while communication services also notched strong gains.Pharmaceuticals giant Eli Lilly <a target="_blank" href="https://markets.businessinsider.com/news/stocks/eli-lilly-stock-price-weight-loss-drugs-q2-earnings-glp1-2024-8">soared 14% after reporting strong earnings</a> in its most recent quarter, helped by big demand for its GLP-1 weight loss drugs. The company's quarterly revenue of $11.30 billion beat analyst estimates of $9.98 billion, and the company raised its annual revenue outlook."We just see unbelievable demand, and we're not even trying that hard to promote this drug. We're not advertising, we told our sales reps to basically just service customers, don't promote," CEO David Ricks said in an interview with CNBC on Thursday.Next week, investors will be tuned into the latest inflation data, with July's consumer price index scheduled to be released on August 14. The data will be the next big input for bets on Fed policy for the rest of the year. Here's where US indexes stood at the 4:00 p.m. closing bell on Thursday:<ul><li><a target="_blank" href="https://markets.businessinsider.com/index/s&amp;p_500?utm_source=markets&amp;utm_medium=ingest%3Futm_source%3Dmarkets&amp;utm_medium=ingest&amp;utm_medium=ingest&amp;utm_source=markets&amp;utm_medium=ingest&amp;utm_source=markets">S&amp;P 500</a>: 5,319.30, up 2.3%</li><li><a target="_blank" href="https://markets.businessinsider.com/index/dow_jones?utm_source=markets&amp;utm_medium=ingest%3Futm_source%3Dmarkets&amp;utm_medium=ingest&amp;utm_medium=ingest&amp;utm_source=markets&amp;utm_medium=ingest&amp;utm_source=markets">Dow Jones Industrial Average</a>: 39,446.82, up 1.76% (+683.30 points)</li><li><a target="_blank" href="https://markets.businessinsider.com/index/nasdaq_composite?utm_source=markets&amp;utm_medium=ingest%3Futm_source%3Dmarkets&amp;utm_medium=ingest&amp;utm_medium=ingest&amp;utm_source=markets&amp;utm_medium=ingest&amp;utm_source=markets">Nasdaq composite</a>: 16,660.02, up 2.87%</li></ul>Here's what else is going on today:<ul><li><a target="_blank" class="" href="https://markets.businessinsider.com/news/stocks/stock-market-outlook-economy-recession-earnings-growth-selloff-unemployment-rate-2024-8">There are two factors that will shape the stock market</a> for the rest of the year. </li><li>The S&amp;P 500 has an <a target="_blank" href="https://markets.businessinsider.com/news/stocks/stock-market-presidential-election-prediction-winner-donald-trump-kamala-harris-2024-8">83% accuracy rate in determining the outcome of presidential elections</a>. Here's what to watch. </li><li>Palantir <a target="_blank" href="https://www.businessinsider.com/author/kelly-cloonan?_gl=1*guld39*_ga*MTY3OTgyNjg0MS4xNzIxMDE2MDM2*_ga_E21CV80ZCZ*MTcyMzE0MDY1Ny4xMDIuMS4xNzIzMTQ1MTYxLjM5LjAuMA..">soared after announcing a deal with Microsoft</a> to sell AI tools to US defense and intelligence agencies.</li><li>The mortgage lock-in effect <a target="_blank" href="https://www.businessinsider.com/housing-market-mortgage-rates-lock-in-effect-economy-interest-rates-2024-8">shaved $20 billion off the US economy last year</a>. </li><li>China's imports last month surged 7.2% year-over-year as the country <a target="_blank" href="https://www.businessinsider.com/china-imports-trade-war-biden-tariffs-chips-demand-economy-2024-8">moves to stockpile tech ahead of trade restrictions</a>, BofA said. </li></ul>In commodities, bonds, and crypto:<ul><li><a target="_blank" href="https://markets.businessinsider.com/commodities/oil-price?utm_medium=ingest&amp;utm_source=markets">West Texas Intermediate</a> crude oil rose 1% to $76.04 a barrel. <a target="_blank" href="https://markets.businessinsider.com/commodities/oil-price?utm_medium=ingest&amp;utm_source=markets">Brent crude</a>, the international benchmark, ticked higher 0.9% to $79.02 a barrel.</li><li><a target="_blank" href="https://markets.businessinsider.com/commodities/gold-price?utm_medium=ingest&amp;utm_source=markets">Gold</a> traded higher at $2,463.30</li><li>The 10-year Treasury yield rose two basis points to 3.98%</li><li><a target="_blank" href="https://markets.businessinsider.com/currencies/btc-usd?utm_medium=ingest&amp;utm_source=markets">Bitcoin</a> rose 8% at $59,549.</li></ul>

Stock market today: S&P 500 has its best day since 2022 as stocks rally after encouraging labor market data

Both <keyword id="19896382" type="General" weightage="20" keywordseo="Sensex" source="keywords">Sensex</keyword> and <keyword id="19896381" type="General" weightage="20" keywordseo="Nifty" source="keywords">Nifty</keyword> regained their mojo back on the final trading session of the week. While Sensex zoomed 1,330.96 points to close the week at over 80,000 (80,436.84 points), Nifty inched up 1.65% to close the day at 24,541.15 points. Out of the 50 Nifty stocks, 47 saw advances, while only 3 declined as of August 16th, 2024. <keyword id="19945574" type="General" weightage="20" keywordseo="Wipro" source="keywords" meta.keywordsubtype="org" meta.entityname="Wipro" meta.hostid="261" meta.entityid="Wipro">Wipro</keyword> (up by 4.23%), Tech Mahindra (up by 3.98%), Grasim (up by 3.65%), Mahindra and Mahindra (up by 3.45%) and Tata Motors (up by 3.36%) were amongst the biggest gainers during the day. On the other hand, Divis Labs (down by 0.62%), SBI Life (down by 0.07%) and Dr. Reddy (down by 0.02%) were amidst the leading laggards. Out of the 2,797 stocks traded during the day, 1,872 saw advances, while 845 declined and another 80 remained unchanged. 95 stocks hit their 52-week high price, while 31 stocks also hit their 52-week lows. 112 stocks hit the upper circuit, or the maximum permissible trading price of a security during a single trading session. This included <keyword id="19945904" type="General" weightage="20" keywordseo="ola" source="keywords">Ola</keyword>, which was up by 20%, Akums Drugs and Pharmaceuticals (up by 10%) and Jindal Poly Films (up by 17.75%). 76 stocks also hit the lower circuit, which included names like MTNL, Dolphin, DCX Systems and more. Most broad market indices closed the day in green, with Nifty Next 50 inching up by 1.82%, Nifty 100 up by 1.66%, Nifty mid cap 50 up by 2.03%, Nifty small cap 50 up by 2.24% and micro caps up by 2.07%. The only exception to this was India VIX, which slipped by 6.68%. Amidst sectoral indices, banks rose by 1.59%, auto was up by 2.01%, financial services was up by 1.7% and FMCG was up by 1.48%. IT (up by 2.89%), media (up by 2.09%) and realty (up by 2.49%) inched up over 2% during the day, while metals and consumer durables moved up by 1% each. Santosh Meena, Head of Research, Swastika Investmart Ltd notes that Indian markets joined the <keyword id="21476120" type="General" weightage="20" keywordseo="global-rally" source="keywords">global rally</keyword> today, rebounding after a brief period of underperformance driven by <keyword id="19950996" type="General" weightage="20" keywordseo="FIIs" source="keywords">FIIs</keyword>' selling in both the cash and F&amp;O segments. Concerns over slightly weaker earnings, high valuations, and the Hindenburg issue had weighed on the market recently. However, a shift in global sentiment from panic to optimism has fueled today's upturn. "Several factors have contributed to this <keyword id="20016146" type="General" weightage="20" keywordseo="bullish-momentum" source="keywords">bullish momentum</keyword>. The fear of a reversal in the yen carry trade has subsided, and strong retail sales figures, along with better-than-expected job data, have alleviated concerns about a potential U.S. recession. Additionally, the market is now fully pricing in a 25 basis point rate cut by the U.S. Federal Reserve in September, further boosting <keyword id="20322632" type="General" weightage="20" keywordseo="investor-confidence" source="keywords">investor confidence</keyword>. If the Nifty can sustain above its 20-DMA, around 24,500, the bullish momentum could extend towards the 24,800-25,000 zone. On the downside, the 24,200 level now serves as a key support", he continued. Ajit Mishra – SVP, Research, Religare Broking Ltd noted that markets staged a robust recovery on Friday, gaining nearly 1.5%, driven by positive global cues. After opening with a gap-up, the Nifty initially lost all its gains in the early hours but rebounded due to strong buying interest in select heavyweight stocks. As a result, the Nifty decisively crossed the resistance at 24,400, closing near the day's high at 24,541.15. The rally was broad-based across sectors, with IT, realty, and auto stocks leading the gains. The broader indices also showed a solid recovery, each advancing nearly 2%. "With the Nifty breaking out of its consolidation phase, it appears poised to close the gap around the 24,700 level. If there is any dip, the 24,300-24,400 zone should provide support. We recommend aligning trades with a focus on stock picking. In the absence of any major domestic triggers, attention will remain on global market performance for further cues", said Mishra.

Stock market closing: Sensex climbs over 1,000 points to close the week, Nifty ends the day at over 24k mark

New Delhi [India], June 10 (ANI): The stock indices closed with a marginal dip after both indices touched an all-time high during Monday's session. The <keyword id="19896382" type="General" weightage="20" keywordseo="Sensex" source="keywords">Sensex</keyword> touched a record high of 77,079 and the <keyword id="20641216" type="General" weightage="20" keywordseo="Nifty-50" source="keywords">Nifty 50</keyword> reached 23,411 points. The Nifty 50 concluded with a decline of 0.13 percent at 23,259 and the Sensex declined 0.27 per cent at 76,490. On Monday, Dalal Street began trading with record highs, primarily driven by banking stocks and Reliance Industries. The Sensex touched a record high of 77,079. According to analysts, the market was watching the global factors today. Selloffs in Europe impacted the global market on Monday, driven by France's decision to call a snap election, affecting the euro, banking stocks, and government bonds, said Varun Aggarwal, MD, Profit Idea. Eurozone bank stocks dropped by 2 per percent's 10-year government bond yield rose by 8 basis points to 3.19 per cent. Italian borrowing costs also increased. In Nifty 50 the top gainers were Reliance Industries, Bharti Airtel, ICICI Bank, SBI, L&amp;T, AdEnterprises, Axis Bank, Sun Pharmaceuticals, Tata Motors, NTPC and Bajaj Motors among others. On Monday, most <keyword id="88972" type="General" weightage="20" keywordseo="IT-stocks" source="Orion">IT stocks</keyword> suffered. The top losers in the Nifty remain Infosys, Bajaj Finance, Mahindra &amp; Mahindra, Wipro, LTIMindtree, and Tech Mahindra. The <keyword id="19925636" type="General" weightage="100" keywordseo="stock-market" source="keywords">stock market</keyword> saw gold prices propping up due to decreased demand, with prices falling by 345 to Rs 71,008 per gram in future trading as speculations reduced their positions. "Among Sectors, Reality, and Media indices rallied over 1 percent whereas IT index was the top loser, shedding 1.84 percent. Technically, after a positive opening entire day the market hovered between 23230 to 23400/76400-77000. Intraday range bound activity and small bearish candle on daily charts after a strong rally indicates indecisiveness between the bulls and bears," opined Shrikant Chouhan, Head Equity Research, Kotak Securities. On the Multi Commodity Exchange, gold contracts for August delivery saw a decline of Rs 345 or 0.48 per cent at Rs 71,008 per 10 grams, with a business turnover of 15,759 lots. Analysts linked the decrease in gold prices to weak global signals. Internationally, gold was down by 0.47 per cent at USD 2,314 per ounce in New York.

You Searched For "pharmaceutical market" and got 13 results

Stock markets end on positive note despite early setbacks

ANI

PresVu eye drops: Why has a pharma company fallen in controversy for claiming to cure near-sightedness?

BI India Bureau

Say bye-bye to reading glasses! Mumbai drug-maker to soon introduce eye drops to treat presbyopia in India

BI India Bureau

Markets to remain shut on November 20 due to Maharashtra elections

BI India Bureau

Emcure Pharma opens for subscription today: Should you subscribe? Know all about it here

Ira Alok Puranik

Bain Capital-backed Emcure Pharma to float ₹1,952-crore IPO on July 3

PTI

Markets pare early gains; trade lower amid muted global market trend

PTI

Is it time we stopped taking over-the-counter fish oil supplements?

Ashmita Gupta

India's pharma exports rise 10% to $27.9 bn in FY24

PTI

These 3 indicators are pointing to a healthy labor market similar to the pre-pandemic boom, according to Goldman Sachs

Christine Ji

Stock market today: S&P 500 has its best day since 2022 as stocks rally after encouraging labor market data

Kelly Cloonan

Stock market closing: Sensex climbs over 1,000 points to close the week, Nifty ends the day at over 24k mark

Ira Alok Puranik

Indian stock market closes in red after touching all-time high; Most IT stocks suffer

ANI

Popular Keywords

Buying Guides